Affordable Access

Is There a Role for Second Line Therapy in Advanced Pancreatic Cancer?

JOP. Journal of the Pancreas
Publication Date
  • Drug Therapy
  • Molecular Targeted Therapy
  • Pancreatic Neoplasms
  • Medicine


FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely used for the first-line treatment for patients with advanced pancreatic adenocarcinoma. Nab-paclitaxel and gemcitabine has replaced the use of many single agent gemcitabine in these patients population. In patients who progress on the first line therapy use of either 5-FU, leucovorin and oxaliplatin (FOLFOX) or gemcitabine and nab-paclitaxel combination has become a de facto standard depending on the chemotherapy they received in first line. Progress made in first line chemotherapy has lead to more interest in refractory pancreatic cancer. This article examines the 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #296, #297, #337, #344, and #381 of the meeting.Image: Chemotherapy regimens tested in refractory pancreatic cancer at 2014 ASCO GI Symposium

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Is there a role for second line therapy in advance...

on JOP : Journal of the pancreas March 2014

Role of gemcitabine as second-line therapy after p...

on Journal of Gastrointestinal On... October 2015

A phase II trial of nab-Paclitaxel as second-line...

on American Journal of Clinical O... April 2013

Second-line therapy for gemcitabine-pretreated adv...

on World Journal of Gastroenterol... Mar 28, 2012
More articles like this..